|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Deregulation of the expression of these interleukins was shown to be responsible for various diseases, such as i) IL-4 vs. immediate type hypersensitivity and ii) IL-6 vs. autoimmunity and multiple myelomas.
|
8691054 |
1989 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Abnormal production of IL-6 has been suggested to be involved in glomerulonephritis, plasmacytomagenesis and in the pathogenesis of autoimmune diseases.
|
2127356 |
1990 |
|
Autoimmune Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Deregulated IL-6 gene expression has been implicated as being involved in the pathogenesis of a number of diseases, especially autoimmune diseases and plasma cell neoplasias.
|
1728989 |
1992 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
In this report, we discuss the possible involvement of interleukin-6 in the pathogenesis of a variety of autoimmune diseases and the regulatory mechanism of expression of the interleukin-6 gene.
|
1627787 |
1992 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
On the other hand, accumulating evidence has revealed that overproduction of IL-6 may be responsible for the pathogenesis and/or several symptoms of a variety of diseases, including autoimmune diseases, malignancies, and viral diseases.
|
1380488 |
1992 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
In accordance with its pleiotropic functions, IL-6 is indicated to be involved in the pathogenesis of several diseases including autoimmunities, lymphoid malignancies and inflammations.
|
1380241 |
1992 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Interleukin-6 (IL-6) is an important immunoregulatory cytokine that has been implicated in a number of fibrotic autoimmune diseases such as scleroderma, interstitial nephritis, and pulmonary interstitial fibrosis.
|
10720455 |
2000 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Neutralization of IL-6 represents an attractive therapeutic option in several diseases, including B cell neoplasia, osteoporosis, and autoimmunity.
|
11254686 |
2001 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
In autoimmune or vasculitic disease, the ability of the IL-6/sIL-6R complex to inhibit apoptosis of autoreactive T-cells may be central to the development of tissue specific autoimmunity.
|
12421676 |
2002 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Hence, NS1 transactivation of proinflammatory cytokine promoters such as IL-6 may be pivotal in triggering the various inflammatory and autoimmune disorders that have been linked to parvovirus B19 infections.
|
11992589 |
2002 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Here we review the evidence for the involvement of IL-6 in the pathophysiology of autoimmune diseases and chronic inflammatory proliferative diseases (CIPD) and discuss the possible molecular mechanisms of its involvement.
|
12220549 |
2003 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
LHGDN |
Here we review the evidence for the involvement of IL-6 in the pathophysiology of autoimmune diseases and chronic inflammatory proliferative diseases (CIPD) and discuss the possible molecular mechanisms of its involvement.
|
12220549 |
2003 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Thus, our results show that autoimmune disease in gp130 mutant mice is caused by increased homeostatic proliferation of CD4+ T cells, which is due to elevated production of IL-7 by nonhematopoietic cells as a result of IL-6 family cytokine-gp130-STAT3 signaling.
|
16717113 |
2006 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Immunoexpression of the CD30 ligand/CD30 and IL-6/IL-6R signals in thyroid autoimmune diseases.
|
16372246 |
2006 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
A study in mice demonstrated that IL-6 promotes the development of a new type of T-helper cells called Th17 cells that impact the pathogenesis of autoimmune diseases.
|
17978466 |
2007 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
In summary, IL-6 trans-signaling into T cells emerges as a key pathway for blockade of the development of adaptive Tregs and thus may play a pivotal role in shifting the balance between effector and regulatory T cell numbers in chronic inflammatory and autoimmune diseases.
|
17675459 |
2007 |
|
Autoimmune Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
High levels of IL-6 and sIL-6R have been reported in several chronic inflammatory and autoimmune diseases as well as in cancer.
|
17465721 |
2007 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Th17 cells, a recently described population, arise in the presence of transforming growth factor beta (TGF-beta) and IL-6 and appear to have an important effector role in inflammation and autoimmunity.
|
18528928 |
2008 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
While experimental models of myocarditis have clearly linked IL-6 to the generation of pathogenic autoreactive T cells, IL-6 has exhibited a protective role in autoimmune disease development in viral-induced disease models.
|
19758168 |
2009 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
CTD_human |
Therefore, the attenuated autoimmunity following loss of IL-4 and IL-6 is dose-dependent, as higher doses of Hg are able to override the attenuation observed using lower doses.
|
19077085 |
2009 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
We have focused on those involved in the proinflammatory response (IL-6, TNF-alpha), apoptosis (TGF-beta, Fas, FasL, C1QA), angiogenesis (IL-8) and autoimmunity (IL-10).
|
19811442 |
2009 |
|
Autoimmune Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Attention will be given to the role of the soluble IL-6R, and we will provide a perspective into the clinical blockade of IL-6 activity in autoimmunity, inflammation, and cancer.
|
21881215 |
2011 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Like other autoimmune diseases, Th17 cells and their effector cytokines (such as interleukin 6) have been implicated in pathogenesis.
|
23202933 |
2012 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Levels of hydrogen peroxide (H(2)O(2)) and interleukin-6 (IL-6), a proinflammation cytokine and a key factor in the pathogenesis of autoimmune diseases, have been reported to be elevated in vitiligo lesions.
|
22871993 |
2012 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Taking these data together, we conclude that IL-6 secretion is a major mechanism of B cell-driven pathogenesis in T cell-mediated autoimmune disease such as EAE and MS.
|
22547654 |
2012 |